A Satyaraddi1, T Velpandian2, S K Sharma1, S Vishnubhatla3, A Sharma4, A Sirohiwal5, G K Makharia6, S Sinha1, A Biswas1, S Singh7. 1. Department of Medicine, All India Institute of Medical Sciences, New Delhi, India. 2. Department of Ocular Pharmacology and Pharmacy, Dr Rajender Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. 3. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India. 4. Medical University, Pleven, Bulgaria. 5. Department of Ophthalmology, Dr Rajender Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. 6. Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India. 7. Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.
Abstract
OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH). METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls). RESULTS: Female sex, body mass index < 17 kg/m(2) and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively). CONCLUSIONS: Plasma RMP levels were higher in cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.
OBJECTIVES: To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH). METHODS: A total of 110 tuberculosis (TB) patients were administered daily anti-tuberculosis treatment and were prospectively followed for the development of DIH. Plasma drug levels were measured at 0, 1, 2 and 4 h on days 1, 7 and 14 of treatment. Plasma drug levels in 15 patients who developed DIH (cases) were compared with 95 patients who did not (controls). RESULTS: Female sex, body mass index < 17 kg/m(2) and baseline serum albumin < 4 g/dl predicted risk of DIH on univariate analyses. Free and total plasma RMP levels (Cmax and AUC0-4) on days 1, 7 and 14 were significantly higher in cases compared to controls and predicted development of DIH. Day 7 total RMP Cmax and AUC0-4 were higher in cases (mean 26.73, standard deviation [SD] 5.72 and 47.58, SD 33.10) than in controls (7.87, SD 10.95 and 14.01, SD 10.69, respectively). CONCLUSIONS: Plasma RMP levels were higher in cases than in controls and independently predicted subsequent development of DIH. The Cmax of Day 7 total RMP level (cut-off 12.50 mg/l) predicted subsequent development of DIH in 93.3% of the patients.
Authors: C Sekaggya-Wiltshire; A von Braun; A U Scherrer; Y C Manabe; A Buzibye; D Muller; B Ledergerber; U Gutteck; N Corti; A Kambugu; P Byakika-Kibwika; M Lamorde; B Castelnuovo; J Fehr; M R Kamya Journal: J Antimicrob Chemother Date: 2017-04-01 Impact factor: 5.790
Authors: Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin Journal: Clin Pharmacokinet Date: 2021-03-10 Impact factor: 6.447
Authors: Ina Jeong; Jong-Sun Park; Young-Jae Cho; Ho Il Yoon; Junghan Song; Choon-Taek Lee; Jae-Ho Lee Journal: J Korean Med Sci Date: 2015-01-21 Impact factor: 2.153
Authors: Natasha Van't Boveneind-Vrubleuskaya; Alper Daskapan; Jos G W Kosterink; Tjip S van der Werf; Susan van den Hof; Jan-Willem C Alffenaar Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240
Authors: Erica C Larson; Christopher D Pond; Prem P Rai; Teatulohi K Matainaho; Pius Piskaut; Michael R Franklin; Louis R Barrows Journal: Evid Based Complement Alternat Med Date: 2016-08-24 Impact factor: 2.629